ClinicalTrials.gg
RecruitingNCT07681973CIPODUpdated Jul 2, 2026

Cognitive and Immunologic Profiles of Patients With Olfactory Dysfunction After Smell Training

An interventional study of Smell Training in Smell Loss and Chronic Rhinosinusitis (CRS), sponsored by The Cleveland Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-02.

Sponsored by The Cleveland Clinic · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Dec 2025, registered May 2026).
  • Started Dec 2025; still recruiting 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
52
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 59 studies in Anosmia with a site in United States — 17 open to participants now, 20 under way, 1 of them phase 3. Anosmia · United States.

Planned enrollment
20th of 43
52 · median 51
Started
2025
with 5 others
No phase
19 of 59
7 open now
Primary completion
2026-12
later than 4 of 19 live
Registered
53rd of 59
by date

Among the 59 studies in Anosmia with a site in United States, this one is the 20th largest by planned enrollment of the 43 interventional ones that give a count, is one of 6 that started in 2025, is one of 19 with no phase, reaches primary completion later than 4 of the 19 other live ones, and was the 53rd registered.

Anosmia

180 studies on the registry are indexed under Anosmia; 45 are open to participants now.

Browse Anosmia studies →

Open to participants now

17 of the 59 studies in Anosmia with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 31 Anosmia studies recruiting now, 14 (45%) set no upper age limit and 9 (29%) stop at 75 or younger; 3 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies in Anosmia with a site in United States, or all of them as a file.
02

Study summary

A research study to assess the baseline olfactory function, mental health status, clinical severity, and immunological profile in patients with smell loss. The impact of a 3-month olfactory training program on smell function, immunological changes, and mental health in patients with smell loss will be evaluated.

The primary purpose of this study is to investigate tissue and blood samples to identify molecules that may be related to smell loss, ultimately aiming to develop future treatments for this condition and correlate with cognition.

Read the detailed description

Adult patients with chronic rhinosinusitis (CRS) with nasal polyps and those experiencing loss of smell will be recruited for the study, along with healthy control participants. We will exclude individuals with unilateral nasal polyps, autoimmune diseases, ciliary disorders, cystic fibrosis, or smell loss due to tumors or trauma.

Assessments will be conducted at baseline and again three months after smell training to evaluate changes in olfactory function. Control patients will only undergo baseline testing with no follow-up assessments needed.

03

Conditions studied

  • Smell Loss
  • Chronic Rhinosinusitis (CRS)

Keywords

  • Smell Loss
  • Chronic Rhinosinusitis
  • Nasal Polyps
  • CRSwNP
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age less than 18 years-old
  • Present to rhinology clinic with CRS with nasal polyps
  • Sense of smell loss for any reason (other than trauma or tumor)

Exclusion criteria

Exclusion Criteria:

  • Patients \< 18 years of age
  • Individuals with unilateral nasal polyps
  • diseases
  • Ciliary disorders
  • Cystic fibrosis
  • Smell loss due to tumors or trauma
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
52 participants (estimated)

Study arms

  • Active comparator
    Group 1: - loss of smell + CRS with nasal polyps (CRSwNP)

    Loss of smell + CRS with nasal polyps (CRSwNP)

    Other: Smell Training

  • Active comparator
    Group 2: - loss of smell with no CRS/no polyps - undergo 3 months of smell training

    Loss of smell + CRS with nasal polyps (CRSwNP) - undergo 3 months of smell training

    Other: Smell Training

  • No intervention
    Control Group 1: - no loss of smell CRS with nasal polyps (CRSwNP)

    No loss of smell CRS with nasal polyps (CRSwNP)

  • No intervention
    Control Group 2: -no loss of smell / no CRS/no polyps

    No loss of smell / no CRS/no polyps

Interventions

  • OtherSmell Training

    Patients experiencing loss of smell from chronic rhinosinusitis (CRS)will undergo smell training.

06

What researchers measure

Primary outcomes

  1. Primary Outcome Measure 1: Baseline olfactory function measured by UPSIT score

    At baseline, participants will complete the University of Pennsylvania Smell Identification Test (UPSIT), a standardized 40-item scratch-and-sniff odor identification test. Scores range from 0 to 40, with higher scores indicating better olfactory function. Unit of Measure: Score on a scale from 0 to 40.

    Time frame: Baseline

  2. Primary Outcome Measure 2: Baseline quality-of-life impact of olfactory dysfunction measured by QOD-NS score

    At baseline, participants will complete the Questionnaire of Olfactory Disorders-Negative Statements (QOD-NS), which measures the negative psychosocial impact of olfactory dysfunction. Scores range from 0 to 48, with higher scores indicating greater negative impact of smell loss on quality of life. Unit of Measure: Score on a scale from 0 to 48.

    Time frame: Baseline

  3. Primary Outcome Measure 3: Baseline cognitive function measured by MMSE score

    At baseline, participants will complete the Mini-Mental State Examination (MMSE), an 11-question cognitive screening tool. Scores range from 0 to 30, with higher scores indicating better cognitive function. Unit of Measure: Score on a scale from 0 to 30.

    Time frame: Baseline

  4. Primary Outcome Measure 4: Baseline nasal cytokine concentration

    At baseline, nasal secretions will be collected from the middle meatus using a polyvinyl alcohol (PVA) sponge and analyzed for cytokine concentrations by multiplex immunoassay. Each cytokine concentration will be reported separately and will not be combined with questionnaire or cognitive assessment scores. Unit of Measure: pg/mL for each cytokine concentration reported separately.

    Time frame: Baseline

Secondary outcomes

  1. Secondary Outcome Measure 1: Change from baseline to Month 3 in olfactory function measured by UPSIT score

    Change from baseline to Month 3 in olfactory function will be assessed using the University of Pennsylvania Smell Identification Test (UPSIT), a standardized 40-item scratch-and-sniff odor identification test. Scores range from 0 to 40, with higher scores indicating better olfactory function. Unit of Measure: Change in score on a scale from 0 to 40.

    Time frame: Baseline to Month 3

  2. Secondary Outcome Measure 2: Change from baseline to Month 3 in quality-of-life impact of olfactory dysfunction measured by QOD-NS score

    Change from baseline to Month 3 in the negative psychosocial impact of olfactory dysfunction will be assessed using the Questionnaire of Olfactory Disorders-Negative Statements (QOD-NS). Scores range from 0 to 48, with higher scores indicating greater negative impact of smell loss on quality of life. Unit of Measure: Change in score on a scale from 0 to 48.

    Time frame: Baseline to Month 3

  3. Secondary Outcome Measure 3: Change from baseline to Month 3 in cognitive function measured by MMSE score

    Change from baseline to Month 3 in cognitive function will be assessed using the Mini-Mental State Examination (MMSE), an 11-question cognitive screening tool. Scores range from 0 to 30, with higher scores indicating better cognitive function. Unit of Measure: Change in score on a scale from 0 to 30.

    Time frame: Baseline to Month 3

  4. Secondary Outcome Measure 4: Change from baseline to Month 3 in nasal cytokine concentration

    Change from baseline to Month 3 in nasal cytokine concentration will be assessed. Nasal secretions will be collected from the middle meatus using a polyvinyl alcohol (PVA) sponge and analyzed by multiplex immunoassay. Each cytokine concentration will be reported separately. Unit of Measure: Change in pg/mL.

    Time frame: Baseline to Month 3

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.

Of 50 non-industry interventional studies with no phase under Anosmia, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 37. This study's planned 12 months is below that.

Counting every sponsor, half of 50 studies reached it within 28 months; a quarter within 14 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2026
First posted
Jul 2, 2026
StartActual
Dec 9, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Mar 31, 2027
Last update
Jul 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07681973
Responsible party
Sponsor
First posted
Jul 2, 2026
Start date
Dec 9, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Jul 2, 2026

Study contacts

John O'Neill
Contact
ONEILLJ2@ccf.org
4405062611
Christopher Novicky
Contact
novickc@ccf.org
216-444-7018
Mohamad Chaaban, MD
principal investigator · The Cleveland Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion